Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/13/12 | $28,000,000 | Series B |
OrbiMed Advisors Osage University Partners The Aurora Funds | undisclosed |
